Sharma Ruchi, Greenhough Sebastian, Medine Claire N, Hay David C
Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, 49 Little France Crescent, Edinburgh,Scotland EH16 4SB, UK.
J Biomed Biotechnol. 2010;2010:236147. doi: 10.1155/2010/236147. Epub 2010 Feb 8.
The liver carries out a range of functions essential for bodily homeostasis. The impairment of liver functions has serious implications and is responsible for high rates of patient morbidity and mortality. Presently, liver transplantation remains the only effective treatment, but donor availability is a major limitation. Therefore, artificial and bioartificial liver devices have been developed to bridge patients to liver transplantation. Existing support devices improve hepatic encephalopathy to a certain extent; however their usage is associated with side effects. The major hindrance in the development of bioartificial liver devices and cellular therapies is the limited availability of human hepatocytes. Moreover, primary hepatocytes are difficult to maintain and lose hepatic identity and function over time even with sophisticated tissue culture media. To overcome this limitation, renewable cell sources are being explored. Human embryonic stem cells are one such cellular resource and have been shown to generate a reliable and reproducible supply of human hepatic endoderm. Therefore, the use of human embryonic stem cell-derived hepatic endoderm in combination with tissue engineering has the potential to pave the way for the development of novel bioartificial liver devices and predictive drug toxicity assays.
肝脏执行一系列对身体内环境稳定至关重要的功能。肝功能受损具有严重影响,是导致患者高发病率和死亡率的原因。目前,肝移植仍然是唯一有效的治疗方法,但供体的可获得性是一个主要限制因素。因此,已经开发出人工和生物人工肝装置,以帮助患者过渡到肝移植。现有的支持装置在一定程度上改善了肝性脑病;然而,其使用会带来副作用。生物人工肝装置和细胞疗法发展的主要障碍是人类肝细胞的可获得性有限。此外,原代肝细胞难以维持,即使使用复杂的组织培养基,随着时间的推移也会丧失肝脏特性和功能。为了克服这一限制,正在探索可再生细胞来源。人类胚胎干细胞就是这样一种细胞资源,已被证明能够产生可靠且可重复的人类肝内胚层供应。因此,将人类胚胎干细胞衍生的肝内胚层与组织工程相结合,有可能为新型生物人工肝装置和预测药物毒性试验的发展铺平道路。